Business Wire

The Estée Lauder Companies Announces Chris Good, Group President, North America to Retire After Exceptional Career

16.11.2021 15:00:00 EET | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Chris Good, Group President, North America, after nearly 25 years with the company, has made the decision to retire effective June 30, 2022. The successor to Chris’ role will be announced shortly, and Chris will partner closely with this individual to support a smooth and successful transition.

“Chris is a visionary, global leader who is deeply admired at ELC and recognized across the beauty industry worldwide. With his extensive international background, Chris’ leadership agility and deep insights into our diverse markets and consumers around the world have made an indelible impact on our business,” said Fabrizio Freda, President and Chief Executive Officer. “Known for his extraordinary business acumen, ability to build high-performing teams, and his track record of achieving strong results in both nascent and established markets globally, Chris has exemplified a commitment to excellence.”

For the past five years, Chris led ELC’s North America business, a highly complex, competitive, and fast-evolving prestige beauty landscape. He oversaw the region’s pivotal retail and organizational transformation, establishing critical capabilities to drive growth and operational efficiencies.

Additionally, Chris elevated data analytics and insights to unlock new and granular opportunities across brands, consumers, and channels. His expertise in channel strategy has accelerated the online business and strengthened the region’s retail relationships, optimizing brick-and-mortar by prioritizing high-performing doors and specialty-multi, and driving brand-building distribution in freestanding stores and emerging channels through modernized omni-experiences.

Chris consistently transformed the business while running it – pivoting with agility and resilience to accelerate recovery in a dynamic environment, while navigating numerous headwinds in North America. Over the past year and a half, he collaborated with his leadership team to steer the region through the complexities of the COVID-19 pandemic, as well as broader macro and social issues, leading with the company’s values and the wellbeing of ELC’s people in mind.

Under Chris’ steady leadership, the North American business returned to growth in fiscal year 2021 and has continued its momentum into the first quarter of fiscal year 2022. To start the new fiscal year, North America delivered strong net sales growth with sales increases across every category. Chris and his leadership team have laid a healthy foundation for long-term, sustainable recovery and growth in North America.

Chris started at ELC in Clinique Marketing in the U.K. and Ireland in 1987. After a period away from the company, where Chris took on senior marketing executive and general management roles for Unilever across Europe, North America and Asia/Pacific, he returned in 2000, as General Manager/Regional Vice President for Clinique, Asia/Pacific, where he helped grow the China and Japan affiliates in their early days. In 2005, he was named General Manager of the recently-established Russian affiliate and in 2008, he became Senior Vice President, Central and Eastern Europe, Middle East, India, and Africa.

Chris was appointed Managing Director, U.K. and Ireland in 2012. While there, he helped pioneer the company’s successful evolution from a traditional department store model into a diversified omnichannel business, leading in brand-building channels such as e/m-commerce and specialty-multi. He was promoted to President, U.K. and Ireland in 2014, and during his tenure, the business generated consistent double-digit, compound annual sales growth and tripled online net sales.

“We are grateful for Chris’ tremendous contributions to our business, and the resolve and dedication he has demonstrated to push boundaries, invent the unexpected and bring the best to ELC and beyond. He has championed our company values and embodied our culture both in the Field and alongside his teams, continuously fueling collaboration and creativity,” said William P. Lauder, Executive Chairman. “Across our global ELC family and the wider industry, Chris has nurtured strong relationships and his hospitable nature, dynamic leadership, and deep retail expertise will be truly missed. On behalf of the company and the Lauder family, I would like to wish Chris the very best in his well-deserved retirement.”

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye